SenesTech, Inc.

Equities

SNES

US81720R5054

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7285 ^USD	-2.84%		+1.48%	-42.64%

Feb. 26	Certain Warrants of SenesTech, Inc. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	CI
Feb. 26	Certain Common Stock of SenesTech, Inc. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	CI

SenesTech, Inc. Announces Exclusive Distribution Agreement with Q-Chem for Evolve Soft Bait in Netherlands

February 15, 2024 at 09:00 am EST

SenesTech, Inc. announced entry into a distribution agreement with Q-chem. The agreement with Q-chem includes initial orders and annual minimums and provides for Q-chem taking the lead on regulatory approvals.

Latest news about SenesTech, Inc.

Certain Warrants of SenesTech, Inc. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
Certain Common Stock of SenesTech, Inc. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
Transcript : SenesTech, Inc., Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
SenesTech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
SenesTech Taps Q-chem to Distribute Pest Control Product in Netherlands	Feb. 15	MT
SenesTech, Inc. Announces Exclusive Distribution Agreement with Q-Chem for Evolve Soft Bait in Netherlands	Feb. 15	CI
Senestech, Inc. Announces Exclusive Distribution Agreement for Evolve Soft Bait in Australia and New Zealand	Feb. 08	CI
SenesTech Signs Distribution Deal With Agro Technic	Feb. 05	MT
Senestech Announces Exclusive Distribution Agreement and Initial Order for Evolve? Soft Bait in Singapore	Feb. 05	CI
Senestech Signs Poppe Enterprises for Evolve? Distribution in Grain Management Market	Jan. 29	CI
SenesTech Partners with Global Leader in Irrigation Solutions to Expand Evolve Soft Bait to Open Field Agriculture Applications	Jan. 08	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Jan. 02	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Jan. 02	MT
Top Midday Gainers	Jan. 02	MT
SenesTech Expands Distribution Deal With Pesterminators; Shares Rise	Jan. 02	MT
SenesTech, Inc. Announces the Expansion of Its Distribution Agreement with Pesterminators Pvt Ltd to Include the Deployment of Evolve	Jan. 02	CI
Top Premarket Gainers	Dec. 28	MT
SenesTech, Inc. Announces Exclusive Distribution Agreement and Initial Order for Evolve Soft Bait in Hong Kong and Macau	Dec. 18	CI
SenesTech's ContraPest Registered for Use in Puerto Rico to Combat Rat Infestations	Dec. 04	CI
SenesTech Closes $5 Million Public Offering	Nov. 29	MT
Top Midday Decliners	Nov. 28	MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell	Nov. 28	MT
Fed Officials Comments Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	Nov. 28	MT
Top Premarket Decliners	Nov. 28	MT
SenesTech Prices $5 Million Public Offering	Nov. 28	MT

Chart SenesTech, Inc.

Duration

Period

More charts

Company Profile

SenesTech, Inc. develops and commercializes products for managing animal pest populations, initially rat populations, through fertility control. The Company has two product lines of fertility control products: ContraPest and Evolve. Its product ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions of the rat population. ContraPest is a highly palatable liquid formulation that reduces fertility in both male and female rats. Additionally, ContraPest does not cause illness in rats, and, therefore, it does not change behavior or result in bait aversion. ContraPest offers a new tool used in coordination with rodenticides as part of an integrated pest management program. The Company's technology can also be applied to other mammalian species.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for SenesTech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7285 USD

Average target price

3.5 USD

Spread / Average Target

+380.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SENESTECH, INC.	-42.64%	3.75M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research